相似文献
1
A Review on the Role of Non-Coding RNAs in the Pathogenesis of Myasthenia Gravis.
Int J Mol Sci. 2021 Nov 30;22(23):12964. doi: 10.3390/ijms222312964.
2
LncRNA OIP5-AS1 modulates the proliferation and apoptosis of Jurkat cells by sponging miR-181c-5p to regulate IL-7 expression in myasthenia gravis.
PeerJ. 2022 May 17;10:e13454. doi: 10.7717/peerj.13454. eCollection 2022.
3
Identification of the regulatory role of lncRNA HCG18 in myasthenia gravis by integrated bioinformatics and experimental analyses.
J Transl Med. 2021 Nov 18;19(1):468. doi: 10.1186/s12967-021-03138-0.
4
Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs.
Front Immunol. 2020 Feb 21;11:151. doi: 10.3389/fimmu.2020.00151. eCollection 2020.
5
Non-Coding RNAs in Myasthenia Gravis: From Immune Regulation to Personalized Medicine.
Cells. 2024 Sep 14;13(18):1550. doi: 10.3390/cells13181550.
6
LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells.
IUBMB Life. 2019 Oct;71(10):1537-1551. doi: 10.1002/iub.2075. Epub 2019 Jun 12.
7
Altered expression of miR-125a-5p in thymoma-associated myasthenia gravis and its down-regulation of foxp3 expression in Jurkat cells.
Immunol Lett. 2016 Apr;172:47-55. doi: 10.1016/j.imlet.2016.02.005. Epub 2016 Feb 11.
8
Circulating microRNAs as potential biomarkers in myasthenia gravis patients.
Ann N Y Acad Sci. 2018 Jan;1412(1):33-40. doi: 10.1111/nyas.13510. Epub 2017 Nov 10.
9
MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine.
Pharmacol Res. 2019 Oct;148:104388. doi: 10.1016/j.phrs.2019.104388. Epub 2019 Aug 8.
10
The key roles of non-coding RNAs in the pathophysiology of hypertension.
Eur J Pharmacol. 2022 Sep 15;931:175220. doi: 10.1016/j.ejphar.2022.175220. Epub 2022 Aug 19.
引用本文的文献
1
Importance of Studying Non-Coding RNA in Children and Adolescents with Type 1 Diabetes.
Biomedicines. 2024 Sep 2;12(9):1988. doi: 10.3390/biomedicines12091988.
2
Non-Coding RNAs in Myasthenia Gravis: From Immune Regulation to Personalized Medicine.
Cells. 2024 Sep 14;13(18):1550. doi: 10.3390/cells13181550.
3
The function of long non-coding RNA IFNG-AS1 in autoimmune diseases.
Hum Cell. 2024 Sep;37(5):1325-1335. doi: 10.1007/s13577-024-01103-9. Epub 2024 Jul 14.
4
High indirect bilirubin levels as an independent predictor of postoperative myasthenic crisis: a single-center, retrospective study.
Front Neurol. 2024 Jan 12;14:1336823. doi: 10.3389/fneur.2023.1336823. eCollection 2023.
5
MicroRNA‑155‑5p affects regulatory T cell activation and immunosuppressive function by targeting BCL10 in myasthenia gravis.
Exp Ther Med. 2023 Nov 9;27(1):6. doi: 10.3892/etm.2023.12293. eCollection 2024 Jan.
6
Dysregulated Long Non-coding RNAs in Myasthenia Gravis- A Mini-Review.
Curr Mol Med. 2025;25(1):2-12. doi: 10.2174/0115665240281531231228051037.
7
Autoimmune myasthenia gravis and COVID-19. A case report-based review.
J Int Med Res. 2023 Aug;51(8):3000605231191025. doi: 10.1177/03000605231191025.
8
Autoimmune myasthenia gravis after COVID-19 in a triple vaccinated patient.
Arch Clin Cases. 2022 Sep 26;9(3):104-107. doi: 10.22551/2022.36.0903.10212. eCollection 2022.
9
Study on the Relationship between lncRNA Gene Polymorphism and Systemic Lupus Erythematosus.
Comput Math Methods Med. 2022 Feb 27;2022:4446016. doi: 10.1155/2022/4446016. eCollection 2022.
本文引用的文献
1
Upregulation of circ-FBL promotes myogenic proliferation in myasthenia gravis by regulation of miR-133/PAX7.
Cell Biol Int. 2021 Nov;45(11):2287-2293. doi: 10.1002/cbin.11676. Epub 2021 Aug 7.
2
Differential Expression of miRNA in the Peripheral Blood Mononuclear Cells in Myasthenia Gravis with Muscle-Specific Receptor Tyrosine Kinase Antibodies.
Crit Rev Eukaryot Gene Expr. 2021;31(2):1-15. doi: 10.1615/CritRevEukaryotGeneExpr.2021037369.
3
MiR-522-3p inhibits proliferation and activation by regulating the expression of SLC31A1 in T cells.
Cytotechnology. 2021 Jun;73(3):483-496. doi: 10.1007/s10616-021-00472-5. Epub 2021 May 7.
4
Expression and Clinical Significance of miR-146a and Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) in Myasthenia Gravis Patient Serum.
Biomed Res Int. 2021 Apr 20;2021:5573469. doi: 10.1155/2021/5573469. eCollection 2021.
5
Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
Muscle Nerve. 2021 Jun;63(6):824-830. doi: 10.1002/mus.27233. Epub 2021 Apr 6.
6
Expression profiling and bioinformatics analysis of exosomal long noncoding RNAs in patients with myasthenia gravis by RNA sequencing.
J Clin Lab Anal. 2021 Apr;35(4):e23722. doi: 10.1002/jcla.23722. Epub 2021 Feb 5.
7
Expression and Significance of MicroRNA-126 and MicroRNA-21 in Peripheral Blood Mononuclear Cells in Patients with Myasthenia Gravis.
Neuroimmunomodulation. 2020;27(3):123-130. doi: 10.1159/000510714. Epub 2021 Feb 3.
8
Construction of a TF-miRNA-gene feed-forward loop network predicts biomarkers and potential drugs for myasthenia gravis.
Sci Rep. 2021 Jan 28;11(1):2416. doi: 10.1038/s41598-021-81962-6.
9
Signaling pathways of genetic variants and miRNAs in the pathogenesis of myasthenia gravis.
Gland Surg. 2020 Dec;9(6):1933-1944. doi: 10.21037/gs-20-39.
10
Gene expression profiling of orbital muscles in treatment-resistant ophthalmoplegic myasthenia gravis.
Orphanet J Rare Dis. 2020 Dec 11;15(1):346. doi: 10.1186/s13023-020-01629-9.
Zotero 插件